Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis

 

 Buy Article Permissions and Reprints

Abstract

Nonalcoholic fatty liver disease represents a wide spectrum of conditions and is currently the most common form of chronic liver disease affecting both adults and children in the United States and many other parts of the world. Great effort has been focused on the development of novel therapies for those patients with the more advanced forms of the disease, in particular those with nonalcoholic steatohepatitis (NASH) and liver fibrosis that can be associated with significant morbidity and mortality. In this review, the authors focus on the role of cell death and sterile inflammatory pathways as well as the self-perpetuating deleterious cycle they may trigger as novel therapeutic targets for the treatment of fibrotic NASH.

• References

• 1 Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012; 61 (2) 141-152
  PubMedGoogle Scholar
• 2 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34 (3) 274-285
  CrossrefPubMedGoogle Scholar
• 3 Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004; 35 (9) 1070-1082
  CrossrefPubMedGoogle Scholar
• 4 Adams LA, Lymp JF, St Sauver J , et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129 (1) 113-121
  CrossrefPubMedGoogle Scholar
• 5 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
  CrossrefPubMedGoogle Scholar
• 6 Angulo P, Kleiner DE, Dam-Larsen S , et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149 (2) 389-97.e10
  CrossrefPubMedGoogle Scholar
• 7 Wong RJ, Aguilar M, Cheung R , et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148 (3) 547-555
  CrossrefPubMedGoogle Scholar
• 8 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52 (5) 1836-1846
  CrossrefPubMedGoogle Scholar
• 9 Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56 (4) 952-964
  CrossrefPubMedGoogle Scholar
• 10 Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion 2011; 83 (1–2) 124-133
  CrossrefPubMedGoogle Scholar
• 11 Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010; 30 (4) 391-401
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013; 10 (11) 627-636
  CrossrefPubMedGoogle Scholar
• 13 Feldstein AE, Canbay A, Angulo P , et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125 (2) 437-443
  CrossrefPubMedGoogle Scholar
• 14 Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol 2015; 1 (1) 17-27
  CrossrefPubMedGoogle Scholar
• 15 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014; 147 (4) 765-783.e4
  CrossrefPubMedGoogle Scholar
• 16 Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39 (2) 273-278
  CrossrefPubMedGoogle Scholar
• 17 Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83 (5) 655-663
  CrossrefPubMedGoogle Scholar
• 18 Kroemer G, Galluzzi L, Vandenabeele P , et al; Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16 (1) 3-11
  CrossrefPubMedGoogle Scholar
• 19 Komatsu M. Liver autophagy: physiology and pathology. J Biochem 2012; 152 (1) 5-15
  CrossrefPubMedGoogle Scholar
• 20 Wree A, Eguchi A, McGeough MD , et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014; 59 (3) 898-910
  CrossrefPubMedGoogle Scholar
• 21 Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5 (11) 897-907
  CrossrefPubMedGoogle Scholar
• 22 Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev 2010; 90 (3) 1165-1194
  CrossrefPubMedGoogle Scholar
• 23 Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 2007; 12 (5) 815-833
  CrossrefPubMedGoogle Scholar
• 24 Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361 (16) 1570-1583
  CrossrefPubMedGoogle Scholar
• 25 Gores GJ, Herman B, Lemasters JJ. Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury. Hepatology 1990; 11 (4) 690-698
  CrossrefPubMedGoogle Scholar
• 26 Holler N, Zaru R, Micheau O , et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1 (6) 489-495
  CrossrefPubMedGoogle Scholar
• 27 Galluzzi L, Kepp O, Kroemer G. RIP kinases initiate programmed necrosis. J Mol Cell Biol 2009; 1 (1) 8-10
  CrossrefPubMedGoogle Scholar
• 28 Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol 2014; 60 (5) 1063-1074
  CrossrefPubMedGoogle Scholar
• 29 Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol 2006; 8 (11) 1812-1825
  CrossrefPubMedGoogle Scholar
• 30 Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004; 308 (3) 1191-1196
  CrossrefPubMedGoogle Scholar
• 31 Holsinger LJ, Coakley DF, Dener JM , et al. Efficacy of a reversible cathepsin B inhibitor in a rodent model of liver fibrosis and human pharmacokinetic profile. Hepatology 2010; 52: 1128A
  PubMedGoogle Scholar
• 32 Wu X, Zhang L, Gurley E , et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 2008; 47 (6) 1905-1915
  CrossrefPubMedGoogle Scholar
• 33 Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99 (12) 2365-2368
  CrossrefPubMedGoogle Scholar
• 34 Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22 (5) 634-638
  PubMedGoogle Scholar
• 35 Gogate P, Ambardekar P, Kulkarni S, Deshpande R, Joshi S, Deshpande M. Comparison of endothelial cell loss after cataract surgery: phacoemulsification versus manual small-incision cataract surgery: six-week results of a randomized control trial. J Cataract Refract Surg 2010; 36 (2) 247-253
  CrossrefPubMedGoogle Scholar
• 36 Boetticher NC, Peine CJ, Kwo P , et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135 (6) 1953-1960
  CrossrefPubMedGoogle Scholar
• 37 Zou C, Ma J, Wang X , et al. Lack of Fas antagonism by Met in human fatty liver disease. Nat Med 2007; 13 (9) 1078-1085
  CrossrefPubMedGoogle Scholar
• 38 Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 2003; 41 (10) 441-449
  CrossrefPubMedGoogle Scholar
• 39 Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest 2012; 92 (5) 713-723
  CrossrefPubMedGoogle Scholar
• 40 Witek RP, Stone WC, Karaca FG , et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009; 50 (5) 1421-1430
  CrossrefPubMedGoogle Scholar
• 41 Anstee QM, Concas D, Kudo H , et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 2010; 53 (3) 542-550
  CrossrefPubMedGoogle Scholar
• 42 Pockros PJ, Schiff ER, Shiffman ML , et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007; 46 (2) 324-329
  CrossrefPubMedGoogle Scholar
• 43 Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010; 31 (9) 969-978
  PubMedGoogle Scholar
• 44 Barreyro FJ, Holod S, Finocchietto PV , et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int 2015; 35 (3) 953-966
  CrossrefPubMedGoogle Scholar
• 45 Ratziu V, Sheikh MY, Sanyal AJ , et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55 (2) 419-428
  CrossrefPubMedGoogle Scholar
• 46 Elbekai RH, Paranjpe MG, Contreras PC, Spada A. Carcinogenicity assessment of the pan-caspase inhibitor, Emricasan, in Tg.rasH2 mice. Regul Toxicol Pharmacol 2015; 72 (2) 169-178
  CrossrefPubMedGoogle Scholar
• 47 Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81 (2) 807-869
  CrossrefPubMedGoogle Scholar
• 48 Wang Y, Singh R, Lefkowitch JH, Rigoli RM, Czaja MJ. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem 2006; 281 (22) 15258-15267
  CrossrefPubMedGoogle Scholar
• 49 Kohl T, Gehrke N, Schad A , et al. Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells. Cell Death Dis 2013; 4: e712
  CrossrefPubMedGoogle Scholar
• 50 Gan LT, Van Rooyen DM, Koina ME, McCuskey RS, Teoh NC, Farrell GC. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol 2014; 61 (6) 1376-1384
  CrossrefPubMedGoogle Scholar
• 51 Kim KY, Kim BC, Xu Z, Kim SJ. Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells. J Biol Chem 2004; 279 (28) 29478-29484
  CrossrefPubMedGoogle Scholar
• 52 Sharma M, Urano F, Jaeschke A. Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes. J Hepatol 2012; 56 (1) 192-198
  CrossrefPubMedGoogle Scholar
• 53 Ibrahim SH, Gores GJ, Hirsova P , et al. Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis. Liver Int 2014; 34 (3) 427-437
  CrossrefPubMedGoogle Scholar
• 54 Jiang JX, Török NJ. MLK3 as a regulator of disease progression in non-alcoholic steatohepatitis. Liver Int 2014; 34 (8) 1131-1132
  CrossrefPubMedGoogle Scholar
• 55 Ichijo H, Nishida E, Irie K , et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997; 275 (5296) 90-94
  CrossrefPubMedGoogle Scholar
• 56 Matsuzawa A, Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 2008; 1780 (11) 1325-1336
  CrossrefPubMedGoogle Scholar
• 57 Yamamoto E, Dong YF, Kataoka K , et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008; 52 (3) 573-580
  CrossrefPubMedGoogle Scholar
• 58 Nakagawa H, Maeda S, Hikiba Y , et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 2008; 135 (4) 1311-1321
  CrossrefPubMedGoogle Scholar
• 59 Lim PL, Liu J, Go ML, Boelsterli UA. The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol Sci 2008; 101 (2) 341-349
  CrossrefPubMedGoogle Scholar
• 60 Lin JH, Zhang JJ, Lin SL, Chertow GM. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron 2015; 129 (1) 29-33
  CrossrefPubMedGoogle Scholar
• 61 Gilead S. A phase 2, dose-ranging, randomized, double-blind, placebo-controlled study of GS-4997 in subjects with pulmonary arterial hypertension. ClinicalTrials.gov I.D. #NCT02234141. Bethesda, MD: National Institutes of Health
  Google Scholar
• 62 Gilead S. A phase 2 double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety, and tolerability of GS-4997 in subjects with diabetic kidney disease. ClinicalTrials.gov I.D. #NCT02177786. Bethesda, MD: National Institutes of Health
  Google Scholar
• 63 Gilead S. A phase 2, randomized, open label study evaluating the safety, tolerability, and efficacy of GS-4997 alone or in combination with simtuzumab (sim) in subjects with nonalcoholic steatohepatitis (NASH) and fibrosis stages F2–F3. ClinicalTrials.gov I.D. #NCT02466516. Bethesda, MD: National Institutes of Health
  Google Scholar
• 64 Zhang D, Lin Han J. Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol 2010; 7 (4) 243-249
  CrossrefPubMedGoogle Scholar
• 65 Zhang YF, He W, Zhang C , et al. Role of receptor interacting protein (RIP)1 on apoptosis-inducing factor-mediated necroptosis during acetaminophen-evoked acute liver failure in mice. Toxicol Lett 2014; 225 (3) 445-453
  CrossrefPubMedGoogle Scholar
• 66 Takemoto K, Hatano E, Iwaisako K , et al. Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure. FEBS Open Bio 2014; 4: 777-787
  CrossrefPubMedGoogle Scholar
• 67 Li JX, Feng JM, Wang Y , et al. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis 2014; 5: e1278
  CrossrefPubMedGoogle Scholar
• 68 Gautheron J, Vucur M, Reisinger F , et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 2014; 6 (8) 1062-1074
  CrossrefPubMedGoogle Scholar
• 69 Mandal P, Berger SB, Pillay S , et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014; 56 (4) 481-495
  CrossrefPubMedGoogle Scholar
• 70 Deutsch M, Graffeo CS, Rokosh R , et al. Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury. Cell Death Dis 2015; 6: e1759
  CrossrefPubMedGoogle Scholar
• 71 Garcia-Martinez I, Mehal WZ. DNA: adding injury to insult. Hepatology 2015; 61 (1) 35-36
  CrossrefPubMedGoogle Scholar
• 72 Garcia-Martinez I, Shaker ME, Mehal WZ. Therapeutic opportunities in damage-associated molecular pattern-driven metabolic diseases. Antioxid Redox Signal 2015;
  PubMedGoogle Scholar
• 73 Mehal WZ. Cells on fire. Sci Am 2015; 312 (6) 44-49
  PubMedGoogle Scholar
• 74 Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418 (6894) 191-195
  CrossrefPubMedGoogle Scholar
• 75 Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274 (28) 19919-19924
  CrossrefPubMedGoogle Scholar
• 76 Yang H, Hreggvidsdottir HS, Palmblad K , et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 2010; 107 (26) 11942-11947
  CrossrefPubMedGoogle Scholar
• 77 Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323 (5922) 1722-1725
  CrossrefPubMedGoogle Scholar
• 78 Venereau E, Casalgrandi M, Schiraldi M , et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209 (9) 1519-1528
  CrossrefPubMedGoogle Scholar
• 79 Tsung A, Sahai R, Tanaka H , et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201 (7) 1135-1143
  CrossrefPubMedGoogle Scholar
• 80 McGill MR, Staggs VS, Sharpe MR, Lee WM, Jaeschke H ; Acute Liver Failure Study Group. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology 2014; 60 (4) 1336-1345
  PubMedGoogle Scholar
• 81 Marques PE, Oliveira AG, Pereira RV , et al. Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice. Hepatology 2015; 61 (1) 348-360
  CrossrefPubMedGoogle Scholar
• 82 Bala S, Petrasek J, Mundkur S , et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012; 56 (5) 1946-1957
  CrossrefPubMedGoogle Scholar
• 83 Kay E, Scotland RS, Whiteford JR. Toll-like receptors: Role in inflammation and therapeutic potential. Biofactors 2014; 40 (3) 284-294
  CrossrefPubMedGoogle Scholar
• 84 Di Virgilio F. P2X receptors and inflammation. Curr Med Chem 2015; 22 (7) 866-877
  CrossrefPubMedGoogle Scholar
• 85 Miura K, Kodama Y, Inokuchi S , et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010; 139 (1) 323-34.e7
  CrossrefPubMedGoogle Scholar
• 86 Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 2010; 4 (4) 659-672
  CrossrefPubMedGoogle Scholar
• 87 Mcdonald KA, Huang H, Tohme S , et al. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling. Mol Med 2014; 20: 639-648
  PubMedGoogle Scholar
• 88 Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37 (12) 3582-3586
  CrossrefPubMedGoogle Scholar
• 89 Garcia-Martinez I, Ouyang X, Santoro N , et al. Elevated plasma DNA in patients with NASH and reduced liver injury in mice with absence of TLR9 on Kupffer cells. Hepatology 2014; 60: 517A
  CrossrefPubMedGoogle Scholar
• 90 Rice JW, Veal JM, Fadden RP , et al. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 2008; 58 (12) 3765-3775
  CrossrefPubMedGoogle Scholar
• 91 Tago K, Tsukahara F, Naruse M, Yoshioka T, Takano K. Hsp90 inhibitors attenuate effect of dexamethasone on activated NF-kappaB and AP-1. Life Sci 2004; 74 (16) 1981-1992
  CrossrefPubMedGoogle Scholar
• 92 Wang X, Wang S, Liu Y , et al. Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells. Oncol Rep 2015; 33 (1) 230-238
  PubMedGoogle Scholar
• 93 López-Castejón G, Pelegrín P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs 2012; 21 (7) 995-1007
  CrossrefPubMedGoogle Scholar
• 94 Hoque R, Vodovotz Y, Mehal W. Therapeutic strategies in inflammasome mediated diseases of the liver. J Hepatol 2013; 58 (5) 1047-1052
  CrossrefPubMedGoogle Scholar
• 95 Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol 2012; 57 (3) 642-654
  CrossrefPubMedGoogle Scholar
• 96 Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243 (1) 136-151
  CrossrefPubMedGoogle Scholar
• 97 Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012; 28: 137-161
  CrossrefPubMedGoogle Scholar
• 98 Henao-Mejia J, Elinav E, Jin C , et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482 (7384) 179-185
  PubMedGoogle Scholar
• 99 Wree A, McGeough MD, Peña CA , et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl) 2014; 92 (10) 1069-1082
  CrossrefPubMedGoogle Scholar
• 100 Han YP, Zhou L, Wang J , et al. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004; 279 (6) 4820-4828
  PubMedGoogle Scholar
• 101 Moltó A, Olivé A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010; 77 (2) 102-107
  CrossrefPubMedGoogle Scholar
• 102 Petrasek J, Bala S, Csak T , et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122 (10) 3476-3489
  CrossrefPubMedGoogle Scholar
• 103 Mack M. A phase 2, double-blind randomized controlled trial of anakinra, pentoxifylline, and zinc compared to methylprednisolone in severe acute alcoholic hepatitis. ClinicalTrials.gov. I.D. #NCT01809132. Bethesda, MD: National Institutes of Health
  Google Scholar
• 104 Coll RC, Robertson A, Butler M, Cooper M, O'Neill LA. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE 2011; 6 (12) e29539
  CrossrefPubMedGoogle Scholar
• 105 Coll RC, Robertson AA, Chae JJ , et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21 (3) 248-255
  CrossrefPubMedGoogle Scholar
• 106 Mridha AWA, Robertson A, Teoh NC , et al. Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH. Paper presented at: the AASLD Liver Meeting; November 13–17, 2015; San Francisco, CA
  PubMedGoogle Scholar